Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q15813
UPID:
TBCE_HUMAN
Alternative names:
Tubulin-folding cofactor E
Alternative UPACC:
Q15813; A8K8C2; B7Z3P1
Background:
Tubulin-specific chaperone E, also known as Tubulin-folding cofactor E, plays a crucial role in the tubulin folding pathway, essential for the proper organization of the microtubule cytoskeleton and mitotic spindle. It is pivotal in maintaining the neuronal microtubule network, highlighting its significance in cellular structure and function.
Therapeutic significance:
Linked to diseases such as Hypoparathyroidism-retardation-dysmorphism syndrome, Kenny-Caffey syndrome 1, and progressive encephalopathy with amyotrophy and optic atrophy, Tubulin-specific chaperone E's involvement in these conditions underscores its potential as a target for therapeutic intervention. Understanding its role could lead to novel treatments for these multisystem disorders.